Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review

Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term oc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurahashi, Kiyoe, Endo, Itsuro, Kondo, Takeshi, Morimoto, Kana, Yoshida, Sumiko, Kuroda, Akio, Aihara, Ken-ichi, Matsuhisa, Munehide, Nakajima, Kohei, Mizobuchi, Yoshifumi, Nagahiro, Shinji, Abe, Masahiro, Fukumoto, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643174/
https://www.ncbi.nlm.nih.gov/pubmed/28824054
http://dx.doi.org/10.2169/internalmedicine.8223-16
Descripción
Sumario:Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.

Ejemplares similares